筛查高骨折风险预防骨折:系统评价与荟萃分析
该系统评价与荟萃分析纳入3项随机研究共42009名参与者,比较基于骨折风险评估和骨密度检测的筛查与常规护理。结果显示筛查可显著降低骨质疏松性骨折、主要骨质疏松性骨折和髋部骨折风险,尤其对髋部骨折效果明显。
要点
- 筛查显著降低主要骨质疏松性骨折(HR=0.91)和髋部骨折(HR=0.80)。
- 筛查未显著降低所有骨折(HR=0.95,95%CI 0.89-1.02)。
- 预防1例骨折需筛查247人(骨质疏松性骨折)或272人(髋部骨折)。
核心结论
- 人群筛查可有效降低骨质疏松性骨折和髋部骨折风险。
- 在老年女性中实施筛查应作为预防骨质疏松性骨折的重要选项。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE和Embase至2019年6月20日。
- 纳入3项随机研究(ROSE、SCOOP、SOS),共42009名参与者。
- 干预组分别有11%、15%、18%的参与者开始药物治疗。
主要发现
- 骨质疏松性骨折HR=0.95(95%CI 0.89-1.00)。
- 主要骨质疏松性骨折HR=0.91(95%CI 0.84-0.98)。
- 髋部骨折HR=0.80(95%CI 0.71-0.91)。
- 所有骨折HR=0.95(95%CI 0.89-1.02)。
- 全因死亡率HR=1.04(95%CI 0.95-1.14)。
关键数值与推荐
- 预防1例骨质疏松性骨折需筛查247人,对应113次骨密度检测和25人治疗。
- 预防1例髋部骨折需筛查272人,对应124次骨密度检测和28人治疗。
临床怎么用
- 对老年女性可考虑实施基于骨折风险评估和骨密度检测的筛查。
- 筛查后对高风险个体启动抗骨质疏松药物治疗。
局限性
- 仅纳入3项随机研究,干预组开始药物治疗的比例分别为11%、15%、18%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This systematic review and meta-analysis showed a significant reduction of (major) osteoporotic fractures and hip fractures after screening using fracture risk assessment and bone densitometry compared with usual care. The results indicate that screening is effective for fracture risk reduction, especially hip fractures. To perform a systematic review and meta-analysis of population screening for high fracture risk on fracture prevention compared with usual care. MEDLINE and Embase were searched for studies published until June 20th 2019. Randomized studies were selected that screened for high fracture risk using at least bone densitometry, screened in a general population, provided subsequent treatment with anti-osteoporosis medication, had a usual care group as comparator, and had at least one fracture-related outcome (all fractures, (major) osteoporotic fractures, or hip fractures). The primary assessment was the hazard ratio (HR) for fracture-related outcomes. All-cause mortality was a secondary outcome. Random-effects models were used to estimate pooled HRs. We identified 1186 potentially eligible articles and included three randomized studies: the ROSE study, the SCOOP study, and the SOS with a total number of N = 42,009 participants. Respectively, 11%, 15%, and 18% of the participants in the intervention group started medication. Meta-analysis showed a statistically significant and clinically relevant reduction of osteoporotic fractures (HR = 0.95, 95% confidence interval (CI) = 0.89-1.00), major osteoporotic fractures (HR = 0.91; 95%CI = 0.84-0.98), and hip fractures (HR = 0.80; 95%CI = 0.71-0.91), but no reduction of all fractures (HR = 0.95; 95%CI = 0.89-1.02). The pooled HR for the secondary outcome all-cause mortality was 1.04 (95% CI = 0.95-1.14). Numbers needed to screen to prevent one fracture were 247 and 272 for osteoporotic fractures and hip fractures, respectively (corresponding to 113 and 124 performed bone densitometry examinations, and 25 and 28 persons being treated). This meta-analysis showed that population screening is effective to reduce osteoporotic fractures and hip fractures. Implementation of screening in older women should be considered as serious option to prevent osteoporotic fractures, especially hip fractures.
引用
- Merlijn T, Swart KMA, van der Horst HE, et al. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int. 2019. PMID: 31838551. doi:10.1007/s00198-019-05226-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。